The Prognostic Impact of Using High-dose Hydralazine in Severe Systolic Heart Failure With Hemodynamically Significant Mitral Regurgitation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.

Also called NCT04217135

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose diagnostic
Phase
Phase 4
Enrolled
  • 400 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04217135
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Taiwan (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04217135. Randomized; no masking; primary purpose diagnostic. Start 2017-01-01 (actual); primary completion 2022-07-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Prognostic Impact of Using High-dose Hydralazine in Severe Systolic Heart Failure With Hemodynamically Significant Mitral Regurgitation
Condition
Systolic Heart Failure Stage D (Disorder)
Condition
Mitral Regurgitation
Intervention (Drug)
evidence-based medications vs. high-dose hydralazine + evidence-based medications
Lead sponsor
Kaohsiung Veterans General Hospital. (class: other)
Collaborator
E-DA Hospital (class: other)

Record details

Record id
cardio:ct-nct04217135
Content hash
4eee860b0c5f63a5cb2df0c5337719aaf5d6484f0b9eff9d40cb0c0f2eb7d963